Breaking News

Frontage Expands Development Services

April 3, 2013

Gains broader DEA license for pain therapeutics and controlled-substances

Frontage Laboratories has received approval to expand its U.S. Drug Enforcement Agency (DEA) license to include formulation development and manufacture of GMP clinical trial materials (CTM) for pain therapeutics and controlled-substances. For the expanded DEA license, Frontage upgraded its facilities, security, and personnel procedures at both of its Exton, PA sites.
 
Frontage supports companies developing DEA Schedules I–V controlled substances and provides analytical development and GMP analytical testing, clinical trial services and bioanalytical support of clinical and preclinical samples.

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016